Availability of new, innovative and specialist cancer drugs in Australia

17 September 2015

© Commonwealth of Australia 2015
ISBN 978-1-76010-224-1

View the report as a single document - (PDF 933KB)

View the report as separate downloadable parts:

Chapter 1 - Introduction (PDF 198KB)

Access to cancer drugs in Australia
The inquiry
The structure of the report
The incidence of cancer in Australia
Cancer as a national health priority
Assessment of cancer medicines in Australia
Alternate access schemes
Comparable international models

Chapter 2 (PDF 222KB)

Timelines for access to new medicines in Australia

Chapter 3 - Affordable access –assessing cost effectiveness (PDF 227KB)

The PBAC assessment framework
Evaluation of cost
Evidentiary requirements
Measuring quality of life - assessing the value of cancer medicines
Committee view

Chapter 4 - Impact of delayed access to cancer medicines on cancer patients (PDF 160KB)

The impact of delayed access on cancer patients and their families
Alternative pathways for access to cancer drugs
Impact on rural patients
Impact on patients with rare cancers
Impact on children, adolescents and young adults
Committee view

Chapter 5 - Alternative access models for new and innovative cancer drugs (PDF 137KB)

Establishment of a specialist cancer drug fund
Managed access models
Improved monitoring and data collection
Committee view

Chapter 6 - Conclusions and recommendations (PDF 49KB)

Enhancing the operation of the TGA and the PBAC
The need for a coordinated review of access pathways for cancer medicines

APPENDIX 1 - Submissions and additional information received by the Committee (PDF 36KB)
APPENDIX 2 - Public hearings (PDF 16KB)

Committee Secretariat contact:

Committee Secretary
Senate Standing Committees on Community Affairs
PO Box 6100
Parliament House
Canberra ACT 2600

Phone: +61 2 6277 3515